Angion Biomedica Competitors

Angion Biomedica (NASDAQ:ANGN) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations and risk.

Earnings & Valuation

This table compares Angion Biomedica and BioAtla's top-line revenue, earnings per share and valuation.

Profitability

This table compares Angion Biomedica and BioAtla's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Angion Biomedica and BioAtla, as reported by MarketBeat.

Angion Biomedica presently has a consensus price target of $59.3333, indicating a potential upside of 283.29%. BioAtla has a consensus price target of $58.00, indicating a potential upside of 22.49%. Given Angion Biomedica's higher possible upside, analysts plainly believe Angion Biomedica is more favorable than BioAtla.

Summary

Angion Biomedica beats BioAtla on 1 of the 1 factors compared between the two stocks.

Angion Biomedica (NASDAQ:ANGN) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations and risk.

Earnings & Valuation

This table compares Angion Biomedica and Immunocore's top-line revenue, earnings per share and valuation.

Profitability

This table compares Angion Biomedica and Immunocore's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Angion Biomedica and Immunocore, as reported by MarketBeat.

Angion Biomedica presently has a consensus price target of $59.3333, indicating a potential upside of 283.29%. Immunocore has a consensus price target of $54.3333, indicating a potential upside of 53.18%. Given Angion Biomedica's stronger consensus rating and higher possible upside, analysts plainly believe Angion Biomedica is more favorable than Immunocore.

Summary

Angion Biomedica beats Immunocore on 3 of the 3 factors compared between the two stocks.

Angion Biomedica (NASDAQ:ANGN) and Cullinan Oncology (NASDAQ:CGEM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations and risk.

Earnings & Valuation

This table compares Angion Biomedica and Cullinan Oncology's top-line revenue, earnings per share and valuation.

Profitability

This table compares Angion Biomedica and Cullinan Oncology's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Angion Biomedica and Cullinan Oncology, as reported by MarketBeat.

Angion Biomedica presently has a consensus price target of $59.3333, indicating a potential upside of 283.29%. Cullinan Oncology has a consensus price target of $48.25, indicating a potential upside of 49.38%. Given Angion Biomedica's stronger consensus rating and higher possible upside, analysts plainly believe Angion Biomedica is more favorable than Cullinan Oncology.

Summary

Angion Biomedica beats Cullinan Oncology on 3 of the 3 factors compared between the two stocks.

Cricut (NASDAQ:EWTX) and Angion Biomedica (NASDAQ:ANGN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and valuation.

Profitability

This table compares Cricut and Angion Biomedica's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings for Cricut and Angion Biomedica, as provided by MarketBeat.com.

Angion Biomedica has a consensus target price of $59.3333, indicating a potential upside of 283.29%. Given Angion Biomedica's higher possible upside, analysts clearly believe Angion Biomedica is more favorable than Cricut.

Valuation and Earnings

This table compares Cricut and Angion Biomedica's gross revenue, earnings per share (EPS) and valuation.

Summary

Angion Biomedica beats Cricut on 2 of the 2 factors compared between the two stocks.

Kinnate Biopharma (NASDAQ:KNTE) and Angion Biomedica (NASDAQ:ANGN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, valuation, risk, analyst recommendations and earnings.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Kinnate Biopharma and Angion Biomedica, as provided by MarketBeat.

Kinnate Biopharma presently has a consensus target price of $52.00, indicating a potential upside of 64.82%. Angion Biomedica has a consensus target price of $59.3333, indicating a potential upside of 283.29%. Given Angion Biomedica's higher possible upside, analysts clearly believe Angion Biomedica is more favorable than Kinnate Biopharma.

Profitability

This table compares Kinnate Biopharma and Angion Biomedica's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Kinnate Biopharma and Angion Biomedica's gross revenue, earnings per share (EPS) and valuation.

Summary

Angion Biomedica beats Kinnate Biopharma on 1 of the 1 factors compared between the two stocks.

Silverback Therapeutics (NASDAQ:SBTX) and Angion Biomedica (NASDAQ:ANGN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, valuation and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Silverback Therapeutics and Angion Biomedica, as provided by MarketBeat.

Silverback Therapeutics currently has a consensus price target of $50.25, indicating a potential upside of 31.99%. Angion Biomedica has a consensus price target of $59.3333, indicating a potential upside of 283.29%. Given Angion Biomedica's higher possible upside, analysts clearly believe Angion Biomedica is more favorable than Silverback Therapeutics.

Profitability

This table compares Silverback Therapeutics and Angion Biomedica's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Silverback Therapeutics and Angion Biomedica's revenue, earnings per share (EPS) and valuation.

Summary

Angion Biomedica beats Silverback Therapeutics on 1 of the 1 factors compared between the two stocks.